Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IOVANCE BIOTHERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for IOVANCE BIOTHERAPEUTICS, INC.

IOVA

IOVANCE BIOTHERAPEUTICS, INC.

About IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics develops personalized TIL (tumor infiltrating lymphocyte) cell therapies for solid tumor cancers, including melanoma and lung cancer. Its core products include Amtagvi, the first FDA-approved TIL therapy for melanoma, and Proleukin, an IL-2 product. The company focuses on manufacturing scalable, proprietary processes and advancing innovative, genetically modified TIL treatments to target diverse, patient-specific neoantigens in global oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IOVANCE BIOTHERAPEUTICS, INC.

1
1
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports 45% Revenue Growth to $71.4 Million in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports 61% Revenue Growth to $263.5 Million in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports $67.5M Revenue in Q3 2025, Net Loss Increases to $91.3M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports 93% Revenue Growth Driven by Amtagvi® Launch

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports $49.3 Million Revenue in Q1 2025, Despite $116.2 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports Significant Revenue Growth and Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments